From: How HIV/AIDS scale-up has impacted on non- HIV priority services in Zambia
Drug/commodity | Normally stocked | Stock-out in last 12 months | Stock out * greater than 1 month |
---|---|---|---|
ARV First-line** | 31 | 2 (6.4%) | 1 (50.0%) |
ARV Second-line | 24 | 2 (8.3%) | 1 (50.0%) |
Lamivudine | 25 | 2 (8%) | 0 (0.0%) |
Rifampicin | 33 | 7 (21.2%) | * 3 (42.9%) |
Cotrimoxazole | 39 | 11 (28.2%) | 4 (36.4%) |
Coartem | 38 | 19 (50%) | * 11 (57.9%) |
Male condom | 37 | 6 (16.2%) | * 2 (33.3%) |
Iron Tablets | 39 | 8 (20.5%) | 3 (37.5%) |
Rehydration salts | 38 | 7 (18.4%) | * 1 (14.3%) |
Ergometrine | 33 | 8 (24.2%) | 4 (50.0%) |
Oxytocin | 23 | 6 (26.1%) | * 2 (33.3%) |
IV giving test | 37 | 6 (16.2%) | * 4 (66.7%) |
Syringes | 38 | 10 (26.3%) | * 3 (30%) |